ABBOTT LABS's ticker is ABT and the CUSIP is 002824100. A total of 2,681 filers reported holding ABBOTT LABS in Q2 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Artemis Wealth Advisors, LLC | 314 | $34,232 | 0.00% |
| Gleason Group, Inc. | 111 | $12,136 | 0.00% |
| FIL Ltd | 24,249 | $2,643,626 | 0.00% |
| Stuart Chaussee & Associates, Inc. | 100 | $10,902 | 0.00% |
| Red Tortoise LLC | 37 | $4,034 | 0.00% |
| Winch Advisory Services, LLC | 50 | $5 | 0.00% |
| Knott David M Jr | 50 | $5 | 0.00% |
| MORGAN DEMPSEY CAPITAL MANAGEMENT LLC | 61 | $6,650 | 0.00% |
| X-Square Capital, LLC | 100,000 | $3 | 0.00% |
| TD AMERITRADE INVESTMENT MANAGEMENT, LLC | 1,357 | $148 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 181,500 | $19,787,130 | 0.00% |
| SkyView Investment Advisors, LLC | 96 | $10 | 0.00% |
| COUNTRY TRUST BANK | 554 | $60,397 | 0.00% |
| Horizons Wealth Management | 21 | $2,289 | 0.00% |
| Brookfield Asset Management | 4,071 | $443,820 | 0.00% |
| Eukles Asset Management | 40 | $4,361 | 0.00% |
| DecisionPoint Financial, LLC | 30 | $3,271 | 0.00% |
| ADIRONDACK RETIREMENT SPECIALISTS, INC. | 19 | $2,071 | 0.00% |
| ROYAL BANK OF CANADA | 24,500 | $2,671,000 | 0.00% |
| True Wealth Design, LLC | 21 | $2,290 | 0.00% |
About ABBOTT LABS
Abbott Labs: A Leading Healthcare Company
Abbott Labs is a global healthcare company that specializes in the development and manufacturing of medical devices, diagnostics, and pharmaceuticals. The company has a strong presence in more than 160 countries and has been in operation for over 130 years.
Abbott Labs has a diverse portfolio of products that cater to various healthcare needs. The company's medical devices range from cardiovascular and diabetes care to neuromodulation and vision care. Abbott Labs also has a strong presence in the diagnostics market, with a focus on infectious diseases, oncology, and genetics. The company's pharmaceuticals division focuses on developing drugs for various therapeutic areas, including immunology, oncology, and neuroscience.
Abbott Labs has a strong leadership team, with Robert B. Ford serving as the company's CEO and Chairman of the Board. Under his leadership, the company has continued to grow and expand its product portfolio. In 2020, Abbott Labs received emergency use authorization from the FDA for its COVID-19 rapid test, which has been instrumental in the fight against the pandemic.
In conclusion, Abbott Labs is a leading healthcare company with a diverse portfolio of products and a strong global presence. The company's commitment to innovation and its focus on meeting the healthcare needs of people around the world make it a valuable investment for stock market investors.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists ABBOTT LABS's shareholders in Q2 2023. To view ABBOTT LABS's shareholder history, click here.